Pregabalin in the treatment of neuropathic pain associated with diabetic peripheral neuropathy

Future Neurology

Volumn 3, Issue 6, 2008, Pages 631-639

  Frank, Bernhard ^a   Cousins, M J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Diabetic; Neuropathic; Neuropathy; Pain; Pregabalin

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; CONOTOXIN; DESIPRAMINE; DEXTROMETHORPHAN; DULOXETINE; FLUPHENAZINE; FLUPIRTINE; GABAPENTIN; IMIPRAMINE; MEMANTINE; NEURODEX; NORTRIPTYLINE; OPIATE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; OXYCODONE; PARACETAMOL; PHENYTOIN; PLACEBO; POTASSIUM CHANNEL KCNQ; PREGABALIN; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; TRAXOPRODIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; CLINICAL TRIAL; COLD; CONFUSION; DEMENTIA; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INCIDENCE; INSOMNIA; MIGRAINE; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; STRUCTURE ANALYSIS; TOOTH PAIN; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 67149126586     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.6.631     Document Type: Article

References (68)

1. Taylor CP, Vartanian MG, Yuen PW, Bigge C, Suman-Chauhan N, Hill DR: Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 14, 11-15 (1993).
2. Crofford LJ, Rowbotham MC, Mease PJ et al.: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52, 1264-1273 (2005).
3. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK: Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 67, 1792-1800 (2006).
4. Hill CM, Balkenohl M, Thomas DW, Walker R, Mathe H, Murray G: Pregabalin in patients with postoperative dental pain. Eur. J. Pain 5, 119-124 (2001).
5. Orstavik K, Namer B, Schmidt R et al.: Abnormal function of C-fibers in patients with diabetic neuropathy. J. Neurosci. 26, 11287-11294 (2006).
6. Brownlee M: Biochemistry and molecular cell biology of diabetic-complications. Nature 414, 813-820 (2001).
7. Luscher TF, Creager MA, Beckman JA, Cosentino F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation 108, 1655-1661 (2003).
8. Creager MA, Luscher TF, Cosentino F, Beckman JA: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108, 1527-1532 (2003).
9. Russell JW, Golovoy D, Vincent AM et al.: High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 16, 1738-1748 (2002).
10. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL: Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis. 6, 347-363 (1999).
11. Schmeichel AM, Schmelzer JD, Low PA: Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52, 165-171 (2003).
12. Fernyhough P, Huang TJ, Verkhratsky A: Mechanism of mitochondrial dysfunction in diabetic sensory neuropathy. J. Peripher. Nerv. Syst. 8, 227-235 (2003).
13. Oaklander A: Diabetic neuropathies. In: Encyclopaedia of Pain. Schmidt RF, Willis WD (Eds). 579-582 (2006).
14. Spruce MC, Potter J, Coppini DV: The pathogenesis and management of painful diabetic neuropathy: a review. Diabet. Med. 20, 88-98 (2003).
15. Woolf CJ, Shortland P, Coggeshall RE: Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 355, 75-78 (1992).
16. Devor M, Schonfeld D, Seltzer Z, Wall PD: Two modes of cutaneous reinnervation following peripheral nerve injury. J. Comp. Neurol. 185, 211-220 (1979).
17. Davies SN, Lodge D: Evidence for involvement of N-methylaspartate receptors in 'wind-up' of class 2 neurones in the dorsal horn of the rat. Brain Res. 424, 402-406 (1987).
18. Scadding JW: Development of ongoing activity, mechanosensitivity, and adrenaline sensitivity in severed peripheral nerve axons. Exp. Neurol. 73, 345-364 (1981).
19. McQuay HJ, Moore RA: An evidence-based resource for pain relief. Oxford medical publications. Oxford University Press, NY, USA 264 (1998).
20. International Diabetes Institute: Australian Diabetes Obesity and Lifestyle Study: Diabesity & Associated Disorders in Australia - 2000: the accelerating epidemic. International Diabetes Institute, Melbourne, Australia. vi, 46 (2991).
21. Blake M, Chaudury M, Deverill C: Health Survey for England 2003. In: High Risk Factors for Cardiovascular Disease. Sproston K, Primatesta P (Eds). The Stationary Office, Norwich, UK (2003).
22. Argoff CE, Cole BE, Fishbain DA, Irving GA: Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin. Proc. 81, S3-S11 (2006).
23. Boulton AJ, Vinik AI, Arezzo JC et al.: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28, 956-962 (2005).
24. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. CD005454 (2005).
25. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A: Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. CD001133 (2005).
26. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O: Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol®): double blind crossover trial. Diabetologia 5, 215-218 (1969).
27. Backonja M, Beydoun A, Edwards KR et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280, 1831-1836 (1998).
28. Chadda VS, Mathur MS: Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J. Assoc. Physicians India 26, 403-406 (1978).
29. Turkington RW: Depression masquerading as diabetic neuropathy. JAMA 243, 1147-1150 (1980).
30. Sindrup SH, Ejlertsen B, Froland A, Sindrup EH, Brosen K, Gram LF: Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur. J. Clin. Pharmacol. 37, 151-153 (1989).
31. Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG, Gonzalez-Barranco J, Lozano-Castaneda O: Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 23, 395-400 (1985).
32. Kvinesdal B, Molin J, Froland A, Gram LF: Imipramine treatment of painful diabetic neuropathy. JAMA 251, 1727-1730 (1984).
33. Max MB, Kishore-Kumar R, Schafer SC et al.: Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 45, 3-9; discussion 1-2 (1991).
34. 2+ channel α(2)δ ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 28, 75-82 (2007).
35. Dooley DJ, Donovan CM, Pugsley TA: Stimulus-dependent modulation of [(3)H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther. 295, 1086-1093 (2000).
36. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett. 280, 107-110 (2000).
37. +-evoked release of [(3)H] glutamate from rat caudial trigeminal nucleus slices. Pain 93, 191-196 (2001).
38. Hoge G: Synthesis of both enantiomers of a P-chirogenic 1,2-bisphospholanoethane ligand via convergent routes and application to rhodium-catalyzed asymmetric hydrogenation of CI-1008 (pregabalin). J. Am. Chem. Soc. 125, 10219-10227 (2003).
39. Field MJ, Bramwell S, Hughes J, Singh L: Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? Pain 83, 303-311 (1999).
40. Field MJ, McCleary S, Hughes J, Singh L: Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80, 391-398 (1999).
41. Houghton AK, Lu Y, Westlund KN: S-(+)-3-isobutylgaba and its stereoisomer reduces the amount of inflammation and hyperalgesia in an acute arthritis model in the rat. J. Pharmacol Exp. Ther. 285, 533-538 (1998).
42. Jones DL, Sorkin LS: Systemic gabapentin and S(+)-3-isobutyl-γ-aminobutyric acid block secondary hyperalgesia. Brain Res. 810, 93-99 (1998).
43. Jun JH, Yaksh TL: The effect of intrathecal gabapentin and 3-isobutyl γ-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth. Analg. 86, 348-354 (1998).
44. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL: Vincristine-induced allodynia in the rat. Pain 93, 69-76 (2001).
45. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN: Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43, 277-283 (2003).
46. Brodie MJ, Wilson EA, Wesche DL et al.: Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46, 1407-1413 (2005).
47. Tassone DM, Boyce E, Guyer J, Nuzum D: Pregabalin: a novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin. Ther. 29, 26-48 (2007).
48. Gajraj NM: Pregabalin: its pharmacology and use in pain management. Anesth. Analg. 105, 1805-1815 (2007).
49. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110, 628-638 (2004).
50. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE: Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 6, 253-260 (2005).
51. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115, 254-263 (2005).
52. Lesser H, Sharma U, LaMoreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63, 2104-2110 (2004).
53. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr: Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur. J. Pain 12, 203-213 (2008).
54. Sang CN, Booher S, Gilron I, Parada S, Max MB: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 96, 1053-1061 (2002).
55. Childers WE Jr, Baudy RB: N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief. J. Med. Chem. 50, 2557-2562 (2007).
56. Kyle DJ, Ilyin VI: Sodium-channel blockers. J. Med. Chem. 50, 2583-2588 (2007).
57. Cox JJ, Reimann F, Nicholas AK et al.: An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894-898 (2006).
58. Fertleman CR, Baker MD, Parker KA et al.: SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52, 767-774 (2006).
59. Ekberg J, Jayamanne A, Vaughan CW et al.: muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc. Natl Acad. Sci. USA 103, 17030-17035 (2006).
60. Jarvis MF, Honore P, Shieh CC et al.: A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl Acad. Sci. USA 104, 8520-8525 (2007).
61. Brochu RM, Dick IE, Tarpley JW et al.: Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. Mol. Pharmacol. 69, 823-832 (2006).
62. 2+ channel alpha2-delta ligands for the treatment of neuropathic pain. J. Med. Chem. 50, 2569-2575 (2007).
63. Munro G, Dalby-Brown W: Kv7 (KCNQ) channel modulators and neuropathic pain. J. Med. Chem. 50, 2576-2582 (2007).
64. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290, 1757-1762 (2003).
65. Hohmann AG, Suplita RL, Bolton NM et al.: An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108-1112 (2005).
66. Bastias AM, Toro CL, Olmos CP: Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy. Rev. Med. Chil. 134, 1507-1515 (2006).
67. Vincler M, Wittenauer S, Parker R, Ellison M, Olivera BM, McIntosh JM: Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors. Proc. Natl Acad. Sci. USA 103, 17880-17884 (2006).
68. Satkunanathan N, Livett B, Gayler K, Sandall D, Down J, Khalil Z: Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res. 1059, 149-158 (2005).